Selected research
Industry Research
Treatment of Blastic-Phase CML Industry Research Report 2026
Market perspective
The global Treatment of Blastic-Phase CML market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Treatment of Blastic-Phase CML is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Treatment of Blastic-Phase CML is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Treatment of Blastic-Phase CML is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Treatment of Blastic-Phase CML include Chia Tai Tianqing Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lunan Pharmaceutical, Hansoh Pharmaceutical, HanHui Pharmaceuticals, Takeda Pharmaceuticals, Sanofi and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Treatment of Blastic-Phase CML market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Treatment of Blastic-Phase CML Market by Company
Chia Tai Tianqing Pharmaceutical
CSPC Ouyi Pharmaceutical
Qilu Pharmaceutical
Lunan Pharmaceutical
Hansoh Pharmaceutical
HanHui Pharmaceuticals
Takeda Pharmaceuticals
Sanofi
Pfizer
Novartis
Dr. Reddy's Laboratories
Bristol Myers Squibb
Beacon Pharmaceuticals
Apotex
Treatment of Blastic-Phase CML Segment by Type
Targeted Therapy with TKIs
Allogeneic BMT or SCT
Chemotherapy
Others
Treatment of Blastic-Phase CML Segment by Application
Hospitals
Clinics
Others
Treatment of Blastic-Phase CML Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatment of Blastic-Phase CML market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Treatment of Blastic-Phase CML and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatment of Blastic-Phase CML.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Treatment of Blastic-Phase CML manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Treatment of Blastic-Phase CML by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Treatment of Blastic-Phase CML in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Targeted Therapy with TKIs
- Allogeneic BMT or SCT
- Chemotherapy
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Chia Tai Tianqing Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Qilu Pharmaceutical
- Lunan Pharmaceutical
- Hansoh Pharmaceutical
- HanHui Pharmaceuticals
- Takeda Pharmaceuticals
- Sanofi
- Pfizer
- Novartis
- Dr. Reddy's Laboratories
- Bristol Myers Squibb
- Beacon Pharmaceuticals
- Apotex
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Treatment of Blastic-Phase CML Market Size (2021-2032)
- 2.2.2 Global Treatment of Blastic-Phase CML Sales (2021-2032)
- 2.2.3 Global Treatment of Blastic-Phase CML Market Average Price (2021-2032)
- 2.3 Treatment of Blastic-Phase CML by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Targeted Therapy with TKIs
- 2.3.3 Allogeneic BMT or SCT
- 2.3.4 Chemotherapy
- 2.3.5 Others
- 2.4 Treatment of Blastic-Phase CML by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Treatment of Blastic-Phase CML Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Treatment of Blastic-Phase CML Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Treatment of Blastic-Phase CML Revenue of Manufacturers (2021-2026)
- 3.4 Global Treatment of Blastic-Phase CML Average Price by Manufacturers (2021-2026)
- 3.5 Global Treatment of Blastic-Phase CML Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Treatment of Blastic-Phase CML, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Treatment of Blastic-Phase CML, Product Type & Application
- 3.8 Global Manufacturers of Treatment of Blastic-Phase CML, Established Date
- 3.9 Global Treatment of Blastic-Phase CML Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chia Tai Tianqing Pharmaceutical
- 4.1.1 Chia Tai Tianqing Pharmaceutical Company Information
- 4.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 4.1.3 Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
- 4.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
- 4.2 CSPC Ouyi Pharmaceutical
- 4.2.1 CSPC Ouyi Pharmaceutical Company Information
- 4.2.2 CSPC Ouyi Pharmaceutical Business Overview
- 4.2.3 CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
- 4.2.5 CSPC Ouyi Pharmaceutical Recent Developments
- 4.3 Qilu Pharmaceutical
- 4.3.1 Qilu Pharmaceutical Company Information
- 4.3.2 Qilu Pharmaceutical Business Overview
- 4.3.3 Qilu Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qilu Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
- 4.3.5 Qilu Pharmaceutical Recent Developments
- 4.4 Lunan Pharmaceutical
- 4.4.1 Lunan Pharmaceutical Company Information
- 4.4.2 Lunan Pharmaceutical Business Overview
- 4.4.3 Lunan Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lunan Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
- 4.4.5 Lunan Pharmaceutical Recent Developments
- 4.5 Hansoh Pharmaceutical
- 4.5.1 Hansoh Pharmaceutical Company Information
- 4.5.2 Hansoh Pharmaceutical Business Overview
- 4.5.3 Hansoh Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hansoh Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
- 4.5.5 Hansoh Pharmaceutical Recent Developments
- 4.6 HanHui Pharmaceuticals
- 4.6.1 HanHui Pharmaceuticals Company Information
- 4.6.2 HanHui Pharmaceuticals Business Overview
- 4.6.3 HanHui Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 HanHui Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio
- 4.6.5 HanHui Pharmaceuticals Recent Developments
- 4.7 Takeda Pharmaceuticals
- 4.7.1 Takeda Pharmaceuticals Company Information
- 4.7.2 Takeda Pharmaceuticals Business Overview
- 4.7.3 Takeda Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Takeda Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio
- 4.7.5 Takeda Pharmaceuticals Recent Developments
- 4.8 Sanofi
- 4.8.1 Sanofi Company Information
- 4.8.2 Sanofi Business Overview
- 4.8.3 Sanofi Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sanofi Treatment of Blastic-Phase CML Product Portfolio
- 4.8.5 Sanofi Recent Developments
- 4.9 Pfizer
- 4.9.1 Pfizer Company Information
- 4.9.2 Pfizer Business Overview
- 4.9.3 Pfizer Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pfizer Treatment of Blastic-Phase CML Product Portfolio
- 4.9.5 Pfizer Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis Treatment of Blastic-Phase CML Product Portfolio
- 4.10.5 Novartis Recent Developments
- 4.11 Dr. Reddy's Laboratories
- 4.11.1 Dr. Reddy's Laboratories Company Information
- 4.11.2 Dr. Reddy's Laboratories Business Overview
- 4.11.3 Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Product Portfolio
- 4.11.5 Dr. Reddy's Laboratories Recent Developments
- 4.12 Bristol Myers Squibb
- 4.12.1 Bristol Myers Squibb Company Information
- 4.12.2 Bristol Myers Squibb Business Overview
- 4.12.3 Bristol Myers Squibb Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bristol Myers Squibb Treatment of Blastic-Phase CML Product Portfolio
- 4.12.5 Bristol Myers Squibb Recent Developments
- 4.13 Beacon Pharmaceuticals
- 4.13.1 Beacon Pharmaceuticals Company Information
- 4.13.2 Beacon Pharmaceuticals Business Overview
- 4.13.3 Beacon Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Beacon Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio
- 4.13.5 Beacon Pharmaceuticals Recent Developments
- 4.14 Apotex
- 4.14.1 Apotex Company Information
- 4.14.2 Apotex Business Overview
- 4.14.3 Apotex Treatment of Blastic-Phase CML Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Apotex Treatment of Blastic-Phase CML Product Portfolio
- 4.14.5 Apotex Recent Developments
5 Global Treatment of Blastic-Phase CML Market Scenario by Region
- 5.1 Global Treatment of Blastic-Phase CML Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Treatment of Blastic-Phase CML Sales by Region: 2021-2032
- 5.2.1 Global Treatment of Blastic-Phase CML Sales by Region: 2021-2026
- 5.2.2 Global Treatment of Blastic-Phase CML Sales by Region: 2027-2032
- 5.3 Global Treatment of Blastic-Phase CML Revenue by Region: 2021-2032
- 5.3.1 Global Treatment of Blastic-Phase CML Revenue by Region: 2021-2026
- 5.3.2 Global Treatment of Blastic-Phase CML Revenue by Region: 2027-2032
- 5.4 North America Treatment of Blastic-Phase CML Market Facts & Figures by Country
- 5.4.1 North America Treatment of Blastic-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Treatment of Blastic-Phase CML Sales by Country (2021-2032)
- 5.4.3 North America Treatment of Blastic-Phase CML Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Treatment of Blastic-Phase CML Market Facts & Figures by Country
- 5.5.1 Europe Treatment of Blastic-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Treatment of Blastic-Phase CML Sales by Country (2021-2032)
- 5.5.3 Europe Treatment of Blastic-Phase CML Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Treatment of Blastic-Phase CML Market Facts & Figures by Country
- 5.6.1 Asia Pacific Treatment of Blastic-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Treatment of Blastic-Phase CML Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Treatment of Blastic-Phase CML Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Treatment of Blastic-Phase CML Market Facts & Figures by Country
- 5.7.1 South America Treatment of Blastic-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Treatment of Blastic-Phase CML Sales by Country (2021-2032)
- 5.7.3 South America Treatment of Blastic-Phase CML Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Treatment of Blastic-Phase CML Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Treatment of Blastic-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Treatment of Blastic-Phase CML Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Treatment of Blastic-Phase CML Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Treatment of Blastic-Phase CML Sales by Type (2021-2032)
- 6.1.1 Global Treatment of Blastic-Phase CML Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2032)
- 6.2 Global Treatment of Blastic-Phase CML Revenue by Type (2021-2032)
- 6.2.1 Global Treatment of Blastic-Phase CML Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2021-2032)
- 6.3 Global Treatment of Blastic-Phase CML Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Treatment of Blastic-Phase CML Sales by Application (2021-2032)
- 7.1.1 Global Treatment of Blastic-Phase CML Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2032)
- 7.2 Global Treatment of Blastic-Phase CML Revenue by Application (2021-2032)
- 7.2.1 Global Treatment of Blastic-Phase CML Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Treatment of Blastic-Phase CML Revenue Market Share by Application (2021-2032)
- 7.3 Global Treatment of Blastic-Phase CML Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Treatment of Blastic-Phase CML Value Chain Analysis
- 8.1.1 Treatment of Blastic-Phase CML Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Treatment of Blastic-Phase CML Production Mode & Process
- 8.2 Treatment of Blastic-Phase CML Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Treatment of Blastic-Phase CML Distributors
- 8.2.3 Treatment of Blastic-Phase CML Customers
9 Global Treatment of Blastic-Phase CML Analyzing Market Dynamics
- 9.1 Treatment of Blastic-Phase CML Industry Trends
- 9.2 Treatment of Blastic-Phase CML Industry Drivers
- 9.3 Treatment of Blastic-Phase CML Industry Opportunities and Challenges
- 9.4 Treatment of Blastic-Phase CML Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst